Real-world experience with Temozolomide & Sativex in patients with recurrent High Grade Gliomas

BACKGROUND: Glioblastoma (GBM) is the most common malignant brain tumour in adults with a median survival from progression of 8 months. A recent phase 1 study of temozolomide (TMZ) and 1:1 CBD:THC (Sativex) offers evidence of efficacy in patients with recurrent GBM (NCT01812603). METHODS: All patien...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Shahabi, Lillie, Le Calvez, Kerlann, Dadhania, Seema, Blake, Catherine, Wang, James, Ingle, Manasi, Anichini, Giulio, Peterson, David, Nandi, Dipankar, Camp, Sophie, Saleem, Waqar, Falconer, Alison, O’Neill, Kevin, Williams, Matt
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Abstracts
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6789945/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz167.057
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items